1-(4-fluorophenyl)-3-(4-hydroxyphenyl)urea

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-fluorophenyl)-3-(4-hydroxyphenyl)urea
• 化学式: C₁₃H₁₁FN₂O₂
• mdl: MFCD11537657
• 分子量: 246.241
• InChiKey: JJZSXJHYXVCAJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  61.4
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(4-fluorophenyl)-3-(4-hydroxyphenyl)urea 在 氨基磺酰氯 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 以90%的产率得到4-(3-(4-fluorophenyl)ureido)phenyl sulfamate
  参考文献：
  名称：

  [EN] CARBONIC ANHYDRASE INHIBITORS
  [FR] INHIBITEURS D'ANHYDRASE CARBONIQUE

  摘要：

  一种碳酸酐酶IX（CA IX）抑制剂，包括一般式化合物：R-NH-CX-NH-(CH2)n-Ar-Q-SO2-NH2或其药用可接受的盐、衍生物或前药；其中n = 0、1或2；Q为O或NH；X为O或S；R包括有机取代基。

  公开号：

  WO2011098610A1
• 作为产物：
  描述：

  4-氟苯胺 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 1-(4-fluorophenyl)-3-(4-hydroxyphenyl)urea
  参考文献：
  名称：

  Structure–Activity Relationship Studies of Pyrazolo[3,4-d]pyrimidine Derivatives Leading to the Discovery of a Novel Multikinase Inhibitor That Potently Inhibits FLT3 and VEGFR2 and Evaluation of Its Activity against Acute Myeloid Leukemia in Vitro and in Vivo

  摘要：

  We describe the structural optimization of a hit compound, 1-(4-(1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)phenyl)-3-(3-methoxyphenyl)urea (1), which exhibits inhibitory activity but low potency against FLT3 and VEGFR2. A series of pyrazolo [3,4-d]pyrimidine derivatives were synthesized, and structure-activity relationship analysis using cell- and transgenic-zebrafish-based assays led to the discovery of a number of compounds that exhibited both high potency against FLT3-driven human acute myeloid leukemia (AML) MV4-11 cells and a considerable antiangiogenic effect in transgenic-zebrafish-based assays. The compound 1-(4-(1H-pyrazolo[3,4-d]pyrimidin-4-yloxy)phenyl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea (33), which exhibited the highest activity in preliminary in vivo anti-AML assays, was chosen for further anti AML studies. The results demonstrated that compound 33 is a multikinase inhibitor that potently inhibits FLT3 and VEGFR2. In an MV4-11 xenograft mouse model, a once daily dose of compound 33 at 10 mg/kg for 18 days led to complete tumor regression without obvious toxicity. Western blot and immunohistochemical analyses were performed to determine the mechanism of action of compound 33.

  DOI：

  10.1021/jm301537p

文献信息

• Palladium-Catalyzed Aerobic Oxidative Carbonylation of Amines Enables the Synthesis of Unsymmetrical N,N′-Disubstituted Ureas
  作者：Honglan Zeng、Hongyan Du、Wei Han、Xu Gong、Jie Zhang

  DOI：10.1055/a-1500-9673

  日期：2021.7

  A ligand-free palladium-catalyzed aerobic oxidative carbonylation of amines for the synthesis of ureas, particular unsymmetrically N,N′-disubstituted ureas, which cannot be accessed by any other palladium-catalyzed oxidative carbonylation of amines to date, is presented. An array of symmetrical and unsymmetrical ureas were straightforwardly synthesized by using inexpensive, readily available, stable

  提出了用于合成脲的无配体的钯催化的胺的好氧氧化羰基化反应，特别是不对称的N，N'-二取代的脲，迄今为止，其他任何钯催化的胺的氧化羰基化反应均无法获得。通过使用廉价，易于获得，稳定和安全的胺，在1个大气压下以良好或优异的收率直接合成了一系列对称和不对称的脲。这种新颖的方法采用氧气作为唯一氧化剂，为基于过渡金属的氧化剂系统提供了有吸引力的替代方法
• Synthesis and investigation of effects of 2-[4-[[(arylamino)carbonyl]amino]phenoxy]-2-methylpropionic acids on the affinity of hemoglobin for oxygen: structure-activity relationships
  作者：Iraj Lalezari、Parviz Lalezari

  DOI：10.1021/jm00130a021

  日期：1989.10

  series of 2-[4-[[[(substituted-phenyl)amino]carbonyl]amino]phenoxy]-2- methylpropionic acids and other substituted phenoxyacetic acids were synthesized and tested for their ability to reduce the affinity of hemoglobin for oxygen. 2-[4-[[[(3,4,5-trichlorophenyl)amino]carbonyl]amino]phenoxy]-2- methylpropionic acid was found to be the most potent compound known. Structure-activity relationships of the compounds

  合成了一系列2- [4-[[[[（（取代-苯基）氨基]羰基]氨基]苯氧基] -2-甲基丙酸和其他取代的苯氧基乙酸，并测试了它们降低血红蛋白对氧的亲和力的能力。发现2- [4-[[[（（3,4,5-三氯苯基）氨基]羰基]氨基]苯氧基] -2-甲基丙酸是已知的最有效的化合物。讨论了合成化合物的构效关系。
• [EN] 6-NITRO-2,3-DIHYDROIMIDAZO[2,1-b]OXAZOLES AND A PROCESS FOR THE PREPARATION THEREOF<br/>[FR] 6-NITRO-2,3-DIHYDROIMIDAZO[2,1-B]OXAZOLES ET LEUR PROCÉDÉ DE PRÉPARATION
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2015049693A1

  公开（公告）日：2015-04-09

  The present invention relates to newer generation of triazoles, tetrazoles, isoxazoles, urea and sulphonamide functionalities containing 6-nitro-2, 3-dihydronitroimidazooxazoles agents of formula 1, their method of preparation, and their use as drugs for treating Mycobacterium tuberculosis,MDR-TB and XDR-TB either alone or in combination with other anti-tubercular agents. In the present invention, new generation 6-nitro-2, 3-dihydronitroimidazooxazoles agents also show acceptable pharmacokinetic properties and synergistic or additive effects with known anti-tubercular drugs.

  本发明涉及新一代三唑类、四唑类、异噁唑类、尿素和磺胺类功能团的含有6-硝基-2,3-二氢硝基咪唑噁唑类化合物的制备方法，以及它们作为治疗结核分枝杆菌、耐药结核分枝杆菌和极耐药结核分枝杆菌的药物的用途，可以单独使用，也可以与其他抗结核药物联合使用。在本发明中，新一代6-硝基-2,3-二氢硝基咪唑噁唑类化合物还表现出可接受的药代动力学性质，并与已知的抗结核药物呈现协同或加成效应。
• [EN] CARBONIC ANHYDRASE INHIBITORS<br/>[FR] INHIBITEURS D'ANHYDRASE CARBONIQUE
  申请人：UNIV FIRENZE

  公开号：WO2011098610A1

  公开（公告）日：2011-08-18

  A carbonic anhydrase IX (CA IX) inhibitor which comprises a compound of general formula: R-NH-CX-NH-(CH2)n-Ar-Q-SO2-NH2 or a pharmaceutically-acceptable salt, derivative or prodrug thereof; wherein n = 0, 1 or 2; Q is O or NH; X is O or S; and R comprises an organic substituent group.

  一种碳酸酐酶IX（CA IX）抑制剂，包括一般式化合物：R-NH-CX-NH-(CH2)n-Ar-Q-SO2-NH2或其药用可接受的盐、衍生物或前药；其中n = 0、1或2；Q为O或NH；X为O或S；R包括有机取代基。
• Synthesis and biological evaluation of diaryl urea derivatives designed as potential anticarcinoma agents using de novo structure-based lead optimization approach
  作者：Fereshteh Azimian、Maryam Hamzeh-Mivehroud、Javid Shahbazi Mojarrad、Salar Hemmati、Siavoush Dastmalchi

  DOI：10.1016/j.ejmech.2020.112461

  日期：2020.9

  compounds based on sorafenib were designed, synthesized and biologically evaluated. Using de novo design method, a library of new ligands was generated and expanded. Considering in silico binding affinity towards VEGFR2, synthetic feasibility, and drug-likeness property, some of the designed ligands were selected for synthesis and screening for their in vitro antiproliferative activities against two cancer

  为了开发阻断VEGFR2和Raf / MEK / ERK丝裂原活化的蛋白激酶信号通路的抑制剂，设计，合成和生物学评估了基于索拉非尼的新化合物。使用从头设计方法，生成并扩展了新的配体库。考虑到对VEGFR2的计算机结合亲和力，合成可行性和药物相似性，选择了一些设计的配体进行合成，并筛选了它们对两种癌细胞系（HT-29和A549）的体外抗增殖活性。四种化合物（13a，14a，14l和15b）显示出更强的抗增殖活性（IC 50为与阳性参考药物索拉非尼（IC 50  = 17.28μM）相比，针对HT-29细胞的HT-29值分别为13.27、6.62、12.74、3.38μM）。值得注意的是，化合物15b表现出最高的活性，尤其是它诱导HT-29凋亡，增加细胞内活性氧水平，将细胞周期阻滞在G0 / G1期，并影响凋亡相关蛋白和细胞周期相关蛋白的表达。15b化合物可有效阻断Raf / MEK / ER